Construction and evaluation of a novel humanized HER2-specific chimeric receptor
文献类型：期刊论文
| 作者 | Sun Meili1; Shi Huan2; Liu Chuanyong1; Liu Jie1; Liu Xianqiang1; Sun Yuping1
|
| 刊名 | BREAST CANCER RESEARCH
 |
| 出版日期 | 2014 |
| 卷号 | 16 |
| ISSN号 | 1465-542X |
| 英文摘要 | Introduction: The human epidermal growth factor receptor 2 (HER2) represents one of the most studied tumor-associated antigens (TAAs) for cancer immunotherapy. The monoclonal antibody (mAb) trastuzumab has improved the outcomes of patients with HER2+ breast cancer. However, a large number of HER2+ tumors are not responsive to, or become resistant to, trastuzumab-based therapy, and thus more effective therapies targeting HER2 are needed. |
| 资助项目 | [National Natural Science Foundation of China] ; [Young Science and Technology Star Program of Jinan] |
| 语种 | 英语 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/124217]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.山东大学 2.中国科学院合肥物质科学研究院肿瘤医院 |
| 推荐引用方式 GB/T 7714 | Sun Meili,Shi Huan,Liu Chuanyong,et al. Construction and evaluation of a novel humanized HER2-specific chimeric receptor[J]. BREAST CANCER RESEARCH,2014,16. |
| APA | Sun Meili,Shi Huan,Liu Chuanyong,Liu Jie,Liu Xianqiang,&Sun Yuping.(2014).Construction and evaluation of a novel humanized HER2-specific chimeric receptor.BREAST CANCER RESEARCH,16. |
| MLA | Sun Meili,et al."Construction and evaluation of a novel humanized HER2-specific chimeric receptor".BREAST CANCER RESEARCH 16(2014). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。